Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | SOS1 | Q07889 | 8/20 | 0.49 |
| ▸ | RHEB | Q15382 | 1/20 | 0.47 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7520505 | 0.92 | KCNH2 (0.65) | BRD4KCNH2KMT2AMEN1RHEB | |
| SCHEMBL7520753 | 0.85 | KMT2A (0.58) | BRD4KCNH2KMT2AMGAMGAA | |
| SCHEMBL7510551 | 0.83 | MGAM (0.65) | BRD4KCNH2KMT2AMEN1SOS1 | |
| SCHEMBL7510547 | 0.83 | MGAM (0.65) | BRD4KCNH2KMT2AMEN1SOS1 | |
| SCHEMBL7512060 | 0.81 | RHEB (0.56) | BRD4KCNH2KMT2AMEN1RHEB | |
| SCHEMBL7511275 | 0.81 | KCNH2 (0.53) | BRD4KCNH2KMT2AMEN1RHEB | |
| SCHEMBL13508758 | 0.81 | KCNH2 (0.86) | BRD4KCNH2KMT2AMEN1SOS1 | |
| SCHEMBL7520453 | 0.78 | DRD2 (0.61) | BRD4KCNH2RHEBDCTPP1 | |
| SCHEMBL7517579 | 0.75 | KDM4E (0.59) | BRD4KCNH2KMT2AMEN1RHEB | |
| SCHEMBL7514352 | 0.75 | MGAM (0.68) | BRD4KCNH2RHEBMGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6452014-B1 | THIAZOLIDINEDIONE COMPOUNDS | GERON CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| WO-2002051409-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | TERT, TERF2, POT1 | BRD4 89/4885KCNH2 4780/4885KMT2A 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.